Bristol Myers Squibb, Inc. announced that Opdivo (nivolumab) plus Yervoy (ipilimumab) with two cycles of chemotherapy showed a durable survival benefit compared to four cycles of chemotherapy alone after two years of follow-up in previously untreated patients with advanced non-small cell lung cancer (NSCLC).
[Bristol Myers Squibb, Inc. (Business Wire, Inc.)]
7753456
{7753456:nan}
apa
50
1
162690
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/